• Je něco špatně v tomto záznamu ?

Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles

M. Fernández-Sánchez, H. Visnova, A. Yuzpe, BM. Klein, B. Mannaerts, JC. Arce, ESTHER-1 and ESTHER-2 Study Group,

. 2019 ; 38 (4) : 528-537. [pub] 20181223

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20022823

RESEARCH QUESTION: Is individualization of dosing with follitropin delta in sequential ovarian stimulation cycles an effective preventive strategy for ovarian hyperstimulation syndrome risk? If so, for which patients does an individualized strategy provide the greatest OHSS risk reduction and/or the need for additional preventive interventions? DESIGN: A secondary analysis of three ovarian stimulation cycles in IVF/intracytoplasmic sperm injection patients included in one randomized, assessor-blinded trial comparing two recombinant FSH preparations (ESTHER-1, NCT01956110), and a second trial in women undergoing up to two additional cycles (ESTHER-2, NCT01956123). Of 1326 women (aged 18-40 years) randomized and treated with follitropin delta or alfa in cycle 1, 513 continued to cycle 2 and 188 to cycle 3. Follitropin delta and alfa doses were maintained/adjusted according to ovarian response in the previous cycle. RESULTS: Individualized dosing with follitropin delta significantly reduced moderate/severe OHSS and/or preventive interventions (P=0.018) versus conventional dosing with follitropin alfa in patients undergoing up to three ovarian stimulation cycles. The greatest benefit was observed in patients in the highest anti-Müllerian hormone (AMH) quartile (P=0.012). On evaluating separately, individualized dosing with follitropin delta significantly lowered the incidences of moderate/severe OHSS (P=0.036) and preventive interventions (P=0.044) versus follitropin alfa. CONCLUSION: An individualized follitropin delta dosing regimen decreased the risk of moderate/severe OHSS as well as the incidence of preventive interventions versus a conventional follitropin alfa regimen. An analysis per AMH quartile indicated that these statistically significant differences are driven mainly by patients with the highest pretreatment AMH levels.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20022823
003      
CZ-PrNML
005      
20201214124839.0
007      
ta
008      
201125s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.rbmo.2018.12.032 $2 doi
035    __
$a (PubMed)30713022
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Fernández-Sánchez, Manuel $u IVI-RMA Seville, Avda. República Argentina 58, Seville, ES-41011, Spain; Departamento de Cirugía, Universidad de Sevilla, Avda. Sánchez Pizjuan S/N, Seville, ES-41009, Spain; Departamento de Biología Molecular e Ingeniería Bioquímica, Universidad Pablo de Olavide, Seville ES-41013, Spain. Electronic address: manuel.fernandez@ivirma.com.
245    10
$a Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles / $c M. Fernández-Sánchez, H. Visnova, A. Yuzpe, BM. Klein, B. Mannaerts, JC. Arce, ESTHER-1 and ESTHER-2 Study Group,
520    9_
$a RESEARCH QUESTION: Is individualization of dosing with follitropin delta in sequential ovarian stimulation cycles an effective preventive strategy for ovarian hyperstimulation syndrome risk? If so, for which patients does an individualized strategy provide the greatest OHSS risk reduction and/or the need for additional preventive interventions? DESIGN: A secondary analysis of three ovarian stimulation cycles in IVF/intracytoplasmic sperm injection patients included in one randomized, assessor-blinded trial comparing two recombinant FSH preparations (ESTHER-1, NCT01956110), and a second trial in women undergoing up to two additional cycles (ESTHER-2, NCT01956123). Of 1326 women (aged 18-40 years) randomized and treated with follitropin delta or alfa in cycle 1, 513 continued to cycle 2 and 188 to cycle 3. Follitropin delta and alfa doses were maintained/adjusted according to ovarian response in the previous cycle. RESULTS: Individualized dosing with follitropin delta significantly reduced moderate/severe OHSS and/or preventive interventions (P=0.018) versus conventional dosing with follitropin alfa in patients undergoing up to three ovarian stimulation cycles. The greatest benefit was observed in patients in the highest anti-Müllerian hormone (AMH) quartile (P=0.012). On evaluating separately, individualized dosing with follitropin delta significantly lowered the incidences of moderate/severe OHSS (P=0.036) and preventive interventions (P=0.044) versus follitropin alfa. CONCLUSION: An individualized follitropin delta dosing regimen decreased the risk of moderate/severe OHSS as well as the incidence of preventive interventions versus a conventional follitropin alfa regimen. An analysis per AMH quartile indicated that these statistically significant differences are driven mainly by patients with the highest pretreatment AMH levels.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a kryoprezervace $7 D015925
650    _2
$a interpretace statistických dat $7 D003627
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fertilizace in vitro $7 D005307
650    _2
$a folikuly stimulující hormon lidský $x aplikace a dávkování $x terapeutické užití $7 D043373
650    _2
$a lidé $7 D006801
650    _2
$a ovariální hyperstimulační syndrom $x prevence a kontrola $7 D016471
650    _2
$a ovarium $x účinky léků $7 D010053
650    12
$a indukce ovulace $x škodlivé účinky $7 D010062
650    _2
$a rekombinantní proteiny $x aplikace a dávkování $x terapeutické užití $7 D011994
650    _2
$a riziko $7 D012306
650    _2
$a intracytoplazmatické injekce spermie $7 D020554
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Visnova, Hana $u IVF CUBE SE, Prague 160 00, Czech Republic.
700    1_
$a Yuzpe, Albert $u Olive Fertility Centre, Vancouver V5Z 3X7, Canada.
700    1_
$a Klein, Bjarke Mirner $u Global Biometrics, Ferring Pharmaceuticals, Copenhagen 2300, Denmark.
700    1_
$a Mannaerts, Bernadette $u Science and Medicine, Ferring Pharmaceuticals, Copenhagen 2300, Denmark.
700    1_
$a Arce, Joan-Carles $u Ferring Pharmaceuticals, US Development, Parsippany, NJ 07054, USA.
710    2_
$a ESTHER-1 and ESTHER-2 Study Group
773    0_
$w MED00007348 $t Reproductive biomedicine online $x 1472-6491 $g Roč. 38, č. 4 (2019), s. 528-537
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30713022 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214124839 $b ABA008
999    __
$a ok $b bmc $g 1595142 $s 1113499
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 38 $c 4 $d 528-537 $e 20181223 $i 1472-6491 $m Reproductive biomedicine online $n Reprod Biomed Online $x MED00007348
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace